Lyra Therapeutics Inc (NAS:LYRA)

$ 0.1806 0.0083 (4.82%) Market Cap: 11.28 Mil Enterprise Value: -5.02 Mil PE Ratio: 0 PB Ratio: 0.55 GF Score: 39/100

Lyra Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023
Lyra Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript
Sep 13, 2023
Lyra Therapeutics Inc to discuss the topline results of the BEACON study Call Transcript
Sep 12, 2023
Lyra Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Lyra Therapeutics Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Lyra Therapeutics Inc at Jefferies London Healthcare Conference Transcript
Nov 17, 2022
Lyra Therapeutics Inc at Stifel Healthcare Conference Transcript
Nov 15, 2022
Lyra Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 14, 2022
Lyra Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 16, 2022
Lyra Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2022
Lyra Therapeutics Inc at William Blair Growth Stock Conference Transcript
Jun 06, 2022
Lyra Therapeutics Inc at Bank of America Healthcare Conference Transcript
May 12, 2022
Q3 2021 Lyra Therapeutics Inc Earnings Call Transcript
Nov 09, 2021

$6.79 (-3.69%)

Earnings
Q2 2021 Lyra Therapeutics Inc Earnings Call Transcript
Aug 09, 2021

$6.69 (-4.02%)

Earnings
Lyra Therapeutics Inc at William Blair Biotech Focus Conference (Virtual) Transcript
Jul 15, 2021
Lyra Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 13, 2021
Q4 2020 Lyra Therapeutics Inc Earnings Call Transcript
Mar 09, 2021

$14.6 (+2.17%)

Earnings
Lyra Therapeutics Inc in Maria Palasis & Strong Leadership in HealthTech Transcript
Oct 08, 2020
Q2 2020 Lyra Therapeutics Inc Earnings Call Transcript
Aug 05, 2020

$13.96 (+1.68%)

Earnings

Lyra Therapeutics Inc at Bank of America Global Healthcare Conference Transcript

May 10, 2023 / 11:35PM GMT

Release Date Price: $2.57 (-3.38%)

Transcript 10-Q8-K

Unidentified Participant

Hello, I think that we're ready to start. So my name is [Perry Numal Lasky]. I am an analyst here at Bank of America, and Jason Gerberry team covers SMid Biotech. I'm pleased to introduce our next speaker Lyra Therapeutics. This is CEO, and I'm here with our CEO, Maria Palasis. And Maria, I'll turn it over to you for a presentation.

Maria Palasis

Lyra Therapeutics Inc - President, Chief Executive Officer, Director

Well, thank you, Perry. Thank you for the introduction and the invitation to present today is really an exciting time at Lyra right now. We've got two products in development, and we have some clinical trial readouts that are coming out very soon here, first one at the end of the year and then another one soon after in the first half of 2024. So Lyra has developed two products to treat chronic rhinosinusitis. And we're actually really proud to be one of the few companies that is developing products for this disease. Chronic rhinosinusitis is an inflammatory disease similar to psoriasis, eczema, but it's localized in the sinuses. And

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.